Dang, ChauEwer, Michael SDelaloge, SuzetteFerrero, Jean-MarcColomer, Ramonde la Cruz-Merino, LuisWerner, Theresa LDadswell, KatherineVerrill, MarkEiger, DanielSarkar, Sriparnade Haas, Sanne LysbetRestuccia, EleonoraSwain, Sandra M2023-05-032023-05-032022-05-242072-6694http://hdl.handle.net/10668/20896BERENICE (NCT02132949) assessed the cardiac safety of the neoadjuvant−adjuvant pertuzumab−trastuzumab-based therapy for high-risk, HER2-positive early breast cancer (EBC). We describe key secondary objectives at final analysis. Eligible patients received dose-dense doxorubicin and cyclophosphamide q2w × 4 ➝ paclitaxel qw × 12 (Cohort A) or 5-fluorouracil, epirubicin, cyclophosphamide q3w × 4 ➝ docetaxel q3w × 4 (B) as per physician’s choice. Pertuzumab−trastuzumab (q3w) was initiated from the taxane start and continued post-surgery to complete 1 year. Median follow-up: 64.5 months. There were no new cardiac issues and a low incidence of Class III/IV heart failure (Cohort B only: one patient (0.5%) in the adjuvant and treatment-free follow-up (TFFU) periods). Fourteen patients (7.7%) had LVEF declines of ≥10% points from baseline toenAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/cardiac safetyearly breast cancerneoadjuvantpertuzumabtrastuzumabresearch article35681574open access10.3390/cancers14112596PMC9179451https://www.mdpi.com/2072-6694/14/11/2596/pdf?version=1662017979https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179451/pdf